Dongcheng Pharmaceutical announced that the phase III clinical trial of fluorine [18F] siruitide injection organized by the holding subsidiary Lan Nacheng has completed the enrollment of all 488 subjects. This drug is a radiologic in vivo diagnostic drug targeting PSMA and is suitable for positron emission tomography imaging of prostate cancer patients. Currently, there are no similar products on the market in China, and similar products are already on the market abroad. According to Lantheus's 2024 report, its product, the 18F-PSMA diagnostic drug PYLARIFY, achieved sales revenue of 1.1 billion US dollars in 2024. The fluorine [18F] siruitide injection project has invested a total of about 119 million yuan in R&D expenses.

Zhitongcaijing · 06/13/2025 08:33
Dongcheng Pharmaceutical announced that the phase III clinical trial of fluorine [18F] siruitide injection organized by the holding subsidiary Lan Nacheng has completed the enrollment of all 488 subjects. This drug is a radiologic in vivo diagnostic drug targeting PSMA and is suitable for positron emission tomography imaging of prostate cancer patients. Currently, there are no similar products on the market in China, and similar products are already on the market abroad. According to Lantheus's 2024 report, its product, the 18F-PSMA diagnostic drug PYLARIFY, achieved sales revenue of 1.1 billion US dollars in 2024. The fluorine [18F] siruitide injection project has invested a total of about 119 million yuan in R&D expenses.